Filing of Form 20-F with SEC

RNS Number : 9502R

AstraZeneca PLC

06 March 2019

 

6 March 2019 07:00 GMT

FILING OF ANNUAL REPORT ON FORM 20-F WITH THE US SECURITIES AND EXCHANGE COMMISSION

AstraZeneca PLC (the Company) announced today that, on 5 March 2019, it filed its 2018 Annual Report on Form 20-F with the US Securities and Exchange Commission (SEC). The document is available for viewing on the SEC website at www.sec.gov and also on the Company's website at www.astrazeneca.com. The Company will send any holder of the Company's securities, upon request, a hard copy of the Company's complete audited financial statements free of charge. Requests may be made by writing to the Company Secretary, AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, UK.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit astrazeneca.com and follow us on Twitter @AstraZeneca.

Media Relations
Gonzalo Viña	UK/Global	[phone]
Rob Skelding	UK/Global	[phone]
Matt Kent	UK/Global	[phone]
Jennifer Hursit	UK/Global	[phone]
Christina Malmberg Hägerstrand	Sweden	[phone]
Michele Meixell	US	[phone]
Investor Relations
Thomas Kudsk Larsen		[phone]
Henry Wheeler	Oncology	[phone]
Christer Gruvris	BioPharma - Cardiovascular; Metabolism	[phone]
Nick Stone	BioPharma - Respiratory; Renal	[phone]
Josie Afolabi	Other	[phone]
Craig Marks	Finance; Fixed Income	[phone]
Jennifer Kretzmann	Retail Investors; Corporate Access	[phone]
US toll-free		[phone]

Adrian Kemp

Company Secretary

AstraZeneca PLC

 

END

 

 

STRSSAESIFUSESD